Cytotoxic T Cells Activated by Self-differentiated Monocyte-derived Dendritic Cells Against Multiple Myeloma Cells

Chiraphapphaiboon, Wannasiri; Luangwattananun, Piriya; Panya, Aussara; Jirapongwattana, Niphat; Punnakitikashem, Primana; CHIEOCHANSIN, THAWEESAK; Junking, Mutita; Yenchitsomanus, Pa‐thai

doi:10.21873/anticanres.15655

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The BCMA‐negative HLA‐A*11:01 KMS‐20 MM cell line and the KKU‐055 cholangiocarcinoma cell line were genetically modified to express the BCMA protein in a stable manner, following previously established protocols. [ 31 ] Given the unavailability of other HLA‐A*11:01 MM cell lines, the KKU‐055 cholangiocarcinoma cell line was opted for, which is homozygous for HLA‐A*11:01, as an alternative target for investigating the cytotoxicity of BCMA‐specific CTLs. Additionally, HLA‐A*02:01 BCMA negative KMM‐1 and BCMA positive L‐363 MM cells were employed as target cells to validate the HLA‐A*11:01‐restricted cytotoxicity.…”

Section: Methodsmentioning

confidence: 99%

“…[ 30 ] In our recent study, we successfully engineered a lentivirus carrying tri‐cistronic cDNAs encoding granulocyte‐macrophage colony‐stimulating factor, interleukin‐4, and BCMA. [ 31 ] This lentivirus was employed to generate self‐differentiated monocyte‐derived dendritic cells expressing BCMA, referred to as SD‐DC‐BCMA. Notably, cytotoxic T cells activated by SD‐DC‐BCMA exhibited robust killing ability against BCMA‐expressing MM cells.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Identification of HLA‐restricted Cytotoxic T Lymphocyte Epitopes of B Cell Maturation Antigen as Promising Peptide Vaccine Candidates for Preventive and Therapeutic Strategies in Multiple Myeloma

Chiraphapphaiboon,

Luangwattananun,

Chieochansin

et al. 2023

Advanced Therapeutics

Self Cite

View full text Add to dashboard Cite

Multiple myeloma (MM) is an incurable hematologic malignancy for which curative treatment remains elusive. Consequently, immunotherapeutic strategies that selectively induce MM‐specific T cell responses by targeting MM‐associated antigens have emerged. This study aims to identify HLA‐restricted cytotoxic T lymphocyte (CTL) epitopes derived from B cell maturation antigen (BCMA) as potential peptide vaccine candidates to advance preventive and therapeutic interventions for MM. BCMA expression in bone marrow tissue samples from 96.8% of MM patients is observed, and the positive membrane BCMA expression is associated with inferior overall survival outcomes. Through an in silico model, four BCMA epitope peptides that exhibit in vitro concentration‐dependent binding to the HLA*A11:01 molecule are identified. Comparative analyses reveal that BCMA‐specific CTLs stimulated by BCMA‐2, BCMA‐3, and BCMA‐4 peptides exhibit significantly greater cytolysis of cancer cells, including BCMA‐overexpressing KMS‐20 and KKU‐055 cells, in comparison to an unpulsed condition or an irrelevant control peptide derived from human immunodeficiency virus‐1 (HIV‐1). Moreover, the observed cytolytic activities of these CTLs are significantly distinct when compared to corresponding BCMA‐negative cells, thereby indicating antigen‐specificity. This study highlights the promising potential of utilizing immunogenic HLA‐A*11:01‐restricted BCMA peptides as a viable approach for cancer vaccination and T cell‐based therapy in the context of MM.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%